Müller-Richter U - Search Results

1

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.

Brandt A, Schultheiss C, Klinghammer K, Schafhausen P, Busch CJ, Blaurock M, Hinke A, Tometten M, Dietz A, Müller-Richter U, Hahn D, Alt J, Stein A, Binder M. Brandt A, et al. Among authors: muller richter u. Front Oncol. 2024 Feb 7;14:1283266. doi: 10.3389/fonc.2024.1283266. eCollection 2024. Front Oncol. 2024. PMID: 38384801 Free PMC article.

2

[Comparative study of spatial imaging techniques in stereo-endoscopy].

Müller-Richter UD, Limberger A, Weber P, Schilling M. Müller-Richter UD, et al. Mund Kiefer Gesichtschir. 2003 May;7(3):157-63. doi: 10.1007/s10006-003-0471-2. Epub 2003 May 1. Mund Kiefer Gesichtschir. 2003. PMID: 12764682 German.

3

[Initial clinical experiences with the Dresden 3D display in conjunction with the Heidelberg Retina Tomograph (HRT)].

Müller-Richter UD, Malig HJ, Schwerdtner A, Lang M, Hille K, Ruprecht KW. Müller-Richter UD, et al. Klin Monbl Augenheilkd. 1999 Sep;215(3):182-5. doi: 10.1055/s-2008-1034696. Klin Monbl Augenheilkd. 1999. PMID: 10528284 German.

4

Three-dimensional analysis of measurements of the Heidelberg Retina Tomograph.

Müller-Richter UD, Malig HJ, Schwerdtner A, Lang M, Hille K, Ruprecht KW. Müller-Richter UD, et al. Graefes Arch Clin Exp Ophthalmol. 2000 Sep;238(9):746-51. doi: 10.1007/s004170000173. Graefes Arch Clin Exp Ophthalmol. 2000. PMID: 11045342

5

[Better evaluation of HRT (Heidelberg Retina Tomography) images by 3-dimensional display].

Müller-Richter UD, Ruprecht KW. Müller-Richter UD, et al. Ophthalmologe. 2001 Sep;98(9):859-63. doi: 10.1007/s003470170062. Ophthalmologe. 2001. PMID: 11594226 German.

6

Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.

Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, Kübler AC, Müller-Richter UDA. Brands RC, et al. Oncol Rep. 2017 Sep;38(3):1877-1885. doi: 10.3892/or.2017.5801. Epub 2017 Jul 10. Oncol Rep. 2017. PMID: 28714017

7

Apoptosis-sensitizing activity of birinapant in head and neck squamous cell carcinoma cell lines.

Brands RC, Scheurer MJJ, Hartmann S, Seher A, Kübler AC, Müller-Richter UDA. Brands RC, et al. Oncol Lett. 2018 Mar;15(3):4010-4016. doi: 10.3892/ol.2018.7783. Epub 2018 Jan 12. Oncol Lett. 2018. PMID: 29467909 Free PMC article.

8

Multi-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro.

Brands RC, De Donno F, Knierim ML, Steinacker V, Hartmann S, Seher A, Kübler AC, Müller-Richter UDA. Brands RC, et al. Oncol Lett. 2019 Sep;18(3):2220-2231. doi: 10.3892/ol.2019.10541. Epub 2019 Jun 28. Oncol Lett. 2019. PMID: 31452723 Free PMC article.

9

Impact of MAGE-A antigens on taxane response in oral squamous cell carcinoma.

Müller-Richter UD, Dowejko A, Driemel O, Reuther T, Reichert TE, Kübler AC. Müller-Richter UD, et al. Oncol Lett. 2010 Jan;1(1):181-185. doi: 10.3892/ol_00000033. Epub 2010 Jan 1. Oncol Lett. 2010. PMID: 22966279 Free PMC article.

10

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

Hartmann S, Brands RC, Küchler N, Fuchs A, Linz C, Kübler AC, Müller-Richter UD. Hartmann S, et al. Oncol Lett. 2015 Aug;10(2):1211-1217. doi: 10.3892/ol.2015.3345. Epub 2015 Jun 9. Oncol Lett. 2015. PMID: 26622654 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters